title: [Antithrombotic therapy in the treatment of STEMI and NSTEMI patients].
abstract: By establishing the Croatian network of primary PCI more patients can now be treated by this method every year. Nevertheless, therapeutic success depends on appropriate, i.e. complete antithrombotic therapy. On the other hand, about half of inhabitants of Croatia have not yet been covered with primary PCI network. Aspirin has an established role in antithrombotic therapy, demonstrated in numerous clinical studies. Thienopirydines, especially clopidogrel, have improved the outcome of interventional cardiology. GP IIb/IIIa receptor inhibitors, despite their high price, pave their way into our daily practice. Heparin is an essential part of therapy for almost all acute coronary syndrome scenarios, but the role of low-molecular heparins is yet to be clarified. Fibrinolytic therapy still "saves lifes". By improving new fibrinolytics, they have become easier to use, entail less side effects and are more efficient.
authors.affiliation: Coronary Unit, Sestre milosrdnice University Hospital, Zagreb, Croatia. Vjeran.Nikolic-Heitzler@zg.htnet.hr
authors.forename: Vjeran
authors.initials: V
authors.lastname: Nikolić Heitzler
authors.forename: Marin
authors.initials: M
authors.lastname: Pavlov
authors.forename: Zdravko
authors.initials: Z
authors.lastname: Babić
authors.forename: Nikola
authors.initials: N
authors.lastname: Bulj
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents